Trial · NCT07513623
Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II
NCT07513623, Phase 2, Not yet recruiting, University of California, San Francisco
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II. Trials, record NCT07513623. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07513623
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II
- NCT number
- NCT07513623
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 117 participants, estimated
- Lead sponsor
- University of California, San Francisco
- Conditions
- Cytomegalovirus (CMV), Anterior Uveitis, Infectious Uveitis, CMV Infection
- Interventions
- Valganciclovir, Ganciclovir (GCV), Placebo
- First posted
- 2026-04-07
- Last updated
- 2026-08-11
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Primary Outcome Measure - Trial I | 7 days | Trial I Aqueous Humor CMV Viral Load at Day 7 |
| Primary | Primary Outcome Measure - Trial II | 12 months | Trial II Recurrence of Anterior Uveitis Inflammation Over 12 Months |
| Secondary | Secondary Outcome Measure - Trial I | 7 days | Trial I proportion of patients achieving clinical inactivity of anterior chamber inflammation at Day 7 |
| Secondary | Secondary Outcome Measure Trial I at 21 days | 21 days | Trial I Clinical proportion of patients achieving clinical inactivity of anterior chamber Inflammation at Day 21 |
| Secondary | Trial I intraocular pressure at 7 days | 7 days | Trial I Intraocular Pressure at Day 7 |
| Secondary | Intraocular pressure at 21 days | 21 days | Trial I Intraocular Pressure at Day 21 |
| Secondary | Visual acuity at 7 days | 7 days | Trial I Visual Acuity at Day 7 |
| Secondary | Visual acuity at 21 days | 21 days | Trial I Visual Acuity at Day 21 |
| Secondary | Topical corticosteroid effect on baseline CMV viral load | 7 days | Change in aqueous humor CMV viral load (IU/mL) per additional topical corticosteroid drop used daily at the time of first anterior chamber paracentesis |
| Secondary | Presence of detectable CMV viral load during recurrence in Trial II | 12 months | Trial II Presence of Detectable Aqueous CMV Viral Load at Time of Recurrence |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers16
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| UG1EY036344 | Systemic and Topical Antiviral Control of Cytomegalovirus Anterior uveitis: TreatmentOutcomes (STACCATO) | Gonzales, John Alexander | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | NATIONAL EYE INSTITUTE | 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07513623
GET https://conductscience.org/api/trials/v1/NCT07513623/registered